Literature DB >> 17454156

A randomized comparison of ovulation induction and hormone profile between the aromatase inhibitor anastrozole and clomiphene citrate in women with infertility.

Hsin-Hung Wu1, Nancy M Wang, Min-Lin Cheng, Jia-Ni Hsieh.   

Abstract

BACKGROUND: IN the present study we evaluated and compared the effects of ovulation and hormonal dynamics induced by anastrozole and clomiphene citrate in women with infertility.
MATERIALS AND METHODS: Thirty-three infertile patients, aged 25-41 years, were enrolled. Patients received either anastrozole 1 mg daily (AI group) or clomiphene citrate 100 mg daily (CC group) from cycle day 3 to day 7. Number of mature follicles (> or =18 mm), endometrial thickness, pregnancy rate and serial hormone profiles (follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E(2)), testosterone and progesterone) were measured on cycle day 3, day 8, day 10, the day of intrauterine insemination (IUI), day 7 after IUI and day 14 after IUI.
RESULTS: Baseline parameters were similar in the two groups, including age, body mass index, infertility duration and day-3 serum hormones except FSH. The mean FSH value on day 3 was significantly different (4.3 mIU/ml in the AI group vs. 6.3 mIU/ml in the CC group; p < 0.05). The women receiving anastrozole had fewer ovulatory follicles (1.2 in the AI group vs. 1.8 in the CC group; p < 0.05) and a thicker endometrium (10.6 mm in the AI group vs. 7.8 mm in the CC group; p < 0.05). The levels of progesterone and testosterone were similar during ovulation stimulation cycles in both groups. On the other hand, the AI group had a significantly higher LH level but a significantly lower E(2) level in the stimulation cycle.
CONCLUSION: Anastrozole has a high pregnancy rate, although it induces fewer ovulatory follicles compared with clomiphene citrate. The two drugs gave different responses of FSH, LH and E2 during stimulation cycles.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17454156     DOI: 10.1080/09513590601137509

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  6 in total

1.  Fertility drugs and young-onset breast cancer: results from the Two Sister Study.

Authors:  Chunyuan Fei; Lisa A Deroo; Dale P Sandler; Clarice R Weinberg
Journal:  J Natl Cancer Inst       Date:  2012-07-06       Impact factor: 13.506

Review 2.  Metformin use in women with polycystic ovary syndrome.

Authors:  Neil P Johnson
Journal:  Ann Transl Med       Date:  2014-06

Review 3.  Agents for ovarian stimulation for intrauterine insemination (IUI) in ovulatory women with infertility.

Authors:  Astrid Ep Cantineau; Anouk Gh Rutten; Ben J Cohlen
Journal:  Cochrane Database Syst Rev       Date:  2021-11-05

4.  Metformin-clinical pharmacology in PCOs.

Authors:  R Dumitrescu; C Mehedintu; I Briceag; V L Purcărea; D Hudita
Journal:  J Med Life       Date:  2015 Apr-Jun

5.  Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment.

Authors:  Chieh-Liang Huang; Yao-Chang Chiang; Wei-Chun Chang; Yu-Ting Su; Juan-Cheng Yang; Wei-Chung Cheng; Hsien-Yuan Lane; Ing-Kang Ho; Wen-Lung Ma
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-05       Impact factor: 5.555

Review 6.  Use of letrozole in assisted reproduction: a systematic review and meta-analysis.

Authors:  Antonio Requena; Julio Herrero; José Landeras; Esperanza Navarro; José L Neyro; Cristina Salvador; Rosa Tur; Justo Callejo; Miguel A Checa; Magí Farré; Juan J Espinós; Francesc Fábregues; María Graña-Barcia
Journal:  Hum Reprod Update       Date:  2008-09-23       Impact factor: 15.610

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.